We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Hvivo Plc | LSE:HVO | London | Ordinary Share | GB00B9275X97 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.60 | 2.08% | 29.50 | 28.50 | 29.50 | 29.00 | 28.90 | 28.90 | 746,449 | 16:35:09 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 48.48M | -776k | -0.0011 | -263.64 | 195.77M |
TIDMHVO
RNS Number : 3938Z
hVIVO plc
14 December 2017
For immediate release 2.00pm: 14 December 2017
HVIVO PLC
("hVIVO" or the "Company")
Director's Dealings
hVIVO plc (AIM: HVO), a specialty biopharma company with discovery and clinical testing capabilities, announces that Dr Trevor Phillips, Executive Chairman of the Company, today purchased 9,035 Ordinary Shares of 5 pence each in the Company ("Ordinary Shares") at a price of 56.0 pence per share.
Following this transaction, Dr Phillips' total interest in the Company is 9,035 Ordinary Shares, representing approximately 0.01% of the Company's issued share capital.
The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail:
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1 Details of the persons discharging managerial responsibilities/persons closely associated --- ----------------------------------------------------- a) Name Dr Trevor Phillips --- ----------------- ---------------------------------- 2 Reason for the notification --- ----------------------------------------------------- a) Position/ Executive Chairman status --- ----------------- ---------------------------------- b) Initial Initial Notification notification/ Amendment --- ----------------- ---------------------------------- 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor --- ----------------------------------------------------- a) Name hVIVO plc --- ----------------- ---------------------------------- b) Legal Entity N/A Identifier --- ----------------- ---------------------------------- 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted --- ----------------------------------------------------- a) Description Ordinary shares of 5 pence each of the financial instrument, GB00B6ZM0X53 type of instrument Identification code --- ----------------- ---------------------------------- b) Nature Acquisition of ordinary shares of the transaction --- ----------------- ---------------------------------- c) Currency GBP --- ----------------- ---------------------------------- d) Price(s) Director Price (p) Volume and volume(s) ----------- ---------- ------- Dr Trevor Phillips 56.0 9,035 ----------- ---------- ------- --- ----------------- e) Aggregated information - Aggregated volume - Price 9,035 - Aggregated 56.0p total GBP5,059.60 --- ----------------- ---------------------------------- f) Date of 14 December 2017 the transaction --- ----------------- ---------------------------------- g) Place of London Stock Exchange, AIM the transaction --- ----------------- ----------------------------------
For further information please contact:
hVIVO plc +44 207 756 1300 Kym Denny (Chief Executive Officer) Graham Yeatman (Chief Financial & Business Officer) Media Enquiries +1 919 710 9658 Susan Flood (Head of Marketing) Numis Securities Limited +44 207 260 1000 Michael Meade / Freddie Barnfield (Nominated Adviser) James Black / Michael Burke (Corporate Broking) FTI Consulting Simon Conway / Victoria Foster Mitchell (UK) +44 203 727 1000 John Capodanno / Evan Smith (US) +1 212 850 5705
Notes to Editors:
hVIVO plc ("hVIVO"), a specialty biopharma company with discovery and clinical testing capabilities, is pioneering a human-based analytical platform to accelerate drug discovery and development in respiratory and infectious diseases. Leveraging human disease models in flu, RSV and asthma exacerbation, the hVIVO platform captures disease in motion, illuminating the entire disease life cycle from healthy to sick and back to health. Based in the UK, market leader hVIVO has conducted more than 50 clinical studies, inoculated over 2500 volunteers and has three first-in-class therapies currently in development with a growing pre-clinical pipeline.
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHGGGMCPUPMGPC
(END) Dow Jones Newswires
December 14, 2017 09:00 ET (14:00 GMT)
1 Year Hvivo Chart |
1 Month Hvivo Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions